Citations

Clear

9383 citation(s) found for "Thomas, PS".

Aerosol Generation Using Different Delivery Methods During Simulated Bronchodilator Challenge Testing in the Pulmonary Function Laboratory
Gmehlin, C.G., Sajgalik, Pavol , Hainy, M., Chul-Ho, K., Johnson, Bruce D. , Allison, Thomas G. , Chul-Ho, K., Lim, Kaiser G. , Niven, Alexander S.

Mayo Clinic

A75. REVISITING CURRENT METHODS IN PULMONARY FUNCTION TESTING | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2626-A2626

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2626 Get It

Critical updates in neuroendocrine tumors: Version 9 American Joint Committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors
Chauhan, Aman, Chan, Kelley , Ge, Phillip S. , Anaya, Daniel A. , Bergsland, Emily K. , Mittra, Erik , Flem, Sherlonda, Brierley, James D. , Asare, Elliot A. , Washington, Kay, Shi, Chanjuan , Kendi, Ayse T, Asare, Elliot A , Shi, Chanjuan , Chauhan, Aman , Hálfdánarson, Þorvarður R. , Bellizzi, Andrew M. , Rindi, Guido , O’Toole, Dermot , Jain, Dhanpat , Dasari, Arvind , Wei, Alice C. , Hope, Thomas A. , Kendi, A. Tuba , Thomas, Samantha Marie

Mayo Clinic

CA: A Cancer Journal for Clinicians | April 29, 2024 | Volume: 74 | Issue: 4 | Pages: 359-367

10.3322/caac.21840 | PMID 38685134 Get It

Abstract The American Joint Committee on Cancer (AJCC) staging system for all cancer sites, including gastroenteropancreatic neuroendocrine tumors (GEP‐NETs), is meant to be dynamic, requiring periodic updates to optimize AJCC staging definitions. This entails the collaboration of experts charged with evaluating new evidence that supports changes to each staging system. GEP‐NETs are the second most prevalent neoplasm of gastrointestinal origin after colorectal cancer. Since publication of the AJCC eighth edition, the World Health Organization has updated the classification and separates grade 3 GEP‐NETs from poorly differentiated neuroendocrine carcinoma. In addition, because of major advancements in diagnostic and therapeutic technologies for GEP‐NETs, AJCC version 9 advocates against the use of serum chromogranin A for the diagnosis and monitoring of GEP‐NETs. Furthermore, AJCC version 9 recognizes the increasing role of endoscopy and endoscopic resection in the diagnosis and management of NETs, particularly in the stomach, duodenum, and colorectum. Finally, T1NXM0 has been added to stage I in these disease sites as well as in the appendix.
AI and machine learning in medical imaging: key points from development to translation
Samala, Ravi K. , Chan, Heang‐Ping , Petrick, Nicholas , Mahmood, Usman , Summers, Ronald M. , Yoshida, Hiroyuki , Huo, Zhimin, Vergara, Daniel , Mazurchuk, Richard, Grizzard, Kevin , Suzuki, Kenji , Armato, Samuel G. , Shukla-Dave, Amita , Chan, Heang-Ping , Mahmood, Usman , Summers, Ronald M , Deserno, Thomas M , Yoshida, Hiroyuki , Drukker, Karen , Huisman, Henkjan , Samala, Ravi K , Drukker, Karen , Shukla‐Dave, Amita , Sahiner, Berkman , Greenspan, Hayit , Tourassi, Georgia D. , Regge, Daniele , Näppi, Janne J. , Chen, Quan , Morra, Lia , Hadjiiski, Lubomir M.

Mayo Clinic

BJR|Artificial Intelligence | April 29, 2024 | Volume: 1 | Issue: 1 | Pages: No page available

10.1093/bjrai/ubae006 | PMID 38828430 Get It

Abstract Innovation in medical imaging artificial intelligence (AI)/machine learning (ML) demands extensive data collection, algorithmic advancements, and rigorous performance assessments encompassing aspects such as generalizability, uncertainty, bias, fairness, trustworthiness, and interpretability. Achieving widespread integration of AI/ML algorithms into diverse clinical tasks will demand a steadfast commitment to overcoming issues in model design, development, and performance assessment. The complexities of AI/ML clinical translation present substantial challenges, requiring engagement with relevant stakeholders, assessment of cost-effectiveness for user and patient benefit, timely dissemination of information relevant to robust functioning throughout the AI/ML lifecycle, consideration of regulatory compliance, and feedback loops for real-world performance evidence. This commentary addresses several hurdles for the development and adoption of AI/ML technologies in medical imaging. Comprehensive attention to these underlying and often subtle factors is critical not only for tackling the challenges but also for exploring novel opportunities for the advancement of AI in radiology.
RANDOMIZED TRIAL COMPARING MICROSERRATED VERSUS CONVENTIONAL INTERNAL LIMITING MEMBRANE FORCEPS FOR INTERNAL LIMITING MEMBRANE PEELING
Hinkle, John C. , Patel, Luv, Ammar, Michael J., Soares, Rebecca R. , Cohen, Michael N. , Hsu, Jason , Yonekawa, Yoshihiro , Regillo, Carl D. , Gupta, Omesh P. , Starr, Matthew R , Starr, Matthew R. , PATEL, SAMIR N. , Ho, Allen C.

Mayo Clinic

Retina | April 29, 2024 | Volume: 44 | Issue: 8 | Pages: 1323-1328

10.1097/iae.0000000000004138 | PMID 39047125 Get It

Purpose: To evaluate anatomic outcomes and surgeon response following the use of microserrated (Sharkskin, Alcon, Forth Worth, TX) internal limiting membrane (ILM) forceps compared with conventional (Grieshaber; Alcon) ILM forceps for peeling of the ILM. Methods: Patients were prospectively assigned in a 1:1 randomized fashion to undergo ILM peeling using microserrated forceps or conventional forceps. Rates of retinal hemorrhages, deep retinal grasps, ILM regrasping, time to ILM removal, and surgeon questionnaire comparing the use of microserrated and conventional ILM forceps were analyzed. Results: A total of 90 eyes of 90 patients were included in this study. The mean number of deep retinal grasps was higher in the conventional forceps group (1.51 ± 1.70 vs. 0.33 ± 0.56, respectively [P < 0.0001]). The mean number of failed ILM grasps was higher with conventional forceps (6.62 ± 3.51 vs. 5.18 ± 2.06 [P = 0.019]). Microserrated forceps provided more comfortability (lower number) in initiating the ILM flap (2.16 ± 0.85 vs. 1.56 ± 0.76, P < 0.001), comfortability in regrasping the ILM flap (2.51 ± 1.01 vs. 1.98 ± 0.89, P = 0.01), and comfortability in completing the ILM flap (2.42 ± 1.03 vs. 1.84 ± 1.02, P = 0.01). Conclusion: Surgeons utilizing the microserrated forceps experienced fewer deep retina grasps and fewer failed ILM grasps compared with conventional ILM forceps. The microserrated forceps was also a more favorable experience subjectively among the surgeons.
A randomized phase III double-blind placebo-controlled trial of first line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)
Mezzanotte-Sharpe, Jessica , O’Neill, Anne, Arteaga, Carlos L. , Yang, Ximing J. , Cella, David , Meropol, Neal J. , Alpaugh, R. Katherine , Saphner, Thomas J. , Swaney, Robert E., Hoelzer, Karen L., Gradishar, William J. , Sundaram, P. Kothai, Jilani, Shamim Z., Perez, Edith A. , Jahanzeb, Mohammad , Reid, Sonya , Mayer, Ingrid A. , Wagner, Lynne I. , Abramson, Vandana G. , Lin, Nancy U. , Wolff, Antonio C. , Sledge, George W.

Mayo Clinic

No container title available | April 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4295044/v1 | PMID 38746356 Get It

Abstract Background In 2008, bevacizumab received accelerated Food and Drug Administration (FDA) approval for use in human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). Based on the preclinical and preliminary clinical activity of the trastuzumab and bevacizumab combination, ECOG-ACRIN E1105 trial was developed to determine if the addition of bevacizumab to a chemotherapy and trastuzumab combination for first-line therapy would improve progression-free survival (PFS) in patients with HER2-positive MBC. Findings: 96 patients were randomized to receive standard first-line chemotherapy and trastuzumab with or without bevacizumab between November 2007 and October 2009, and 93 began protocol therapy. Induction therapy was given for 24 weeks, followed by maintenance trastuzumab with or without bevacizumab. 60% (56/93) began carboplatin and 74% (69/93) completed 6 cycles of induction therapy. Primary endpoint was PFS. Median PFS was 11.1 and 13.8 months for placebo and bevacizumab arms, respectively (hazard ratio [HR] 95%, Confidence Interval [Cl] for bevacizumab vs. placebo: 0.73 [0.43–1.23], p = 0.24), and at a median follow-up of 70.7 months, median survival was 49.1 and 63 months (HR [95% Cl] for OS: 1.09 [0.61–1.97], p = 0.75). The most common toxicities across both arms were neutropenia and hypertension, with left ventricular systolic dysfunction, fatigue, and sensory neuropathy reported more frequently with bevacizumab. Conclusions In this trial, the addition of bevacizumab did not improve outcomes in patients with metastatic HER2-positive breast cancer. Although the trial was underpowered due to smaller than anticipated sample size, these findings corroborated other clinical trials during this time.
Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
Chen, Wendy Y. , Hahn, Olwen, Briccetti, Frederick , Irvin, William , Symington, Banu , Visvanathan, Kala , Pohlmann, Paula R. , Openshaw, Thomas H. , Weiss, Anna , Visvanathan, Kala , Pohlmann, Paula , Ballman, Karla V. , Partridge, Ann H. , Winer, Eric P. , Carey, Lisa A. , Holmes, Michelle D

Mayo Clinic

JAMA | April 29, 2024 | Volume: 331 | Issue: 20 | Pages: 1714

10.1001/jama.2024.4840 | PMID 38683596 Get It

Importance Observational studies of survivors of breast cancer and prospective trials of aspirin for cardiovascular disease suggest improved breast cancer survival among aspirin users, but prospective studies of aspirin to prevent breast cancer recurrence are lacking. Objective To determine whether aspirin decreases the risk of invasive cancer events among survivors of breast cancer. Design, Setting, and Participants A011502, a phase 3, randomized, placebo-controlled, double-blind trial conducted in the United States and Canada with 3020 participants who had high-risk nonmetastatic breast cancer, enrolled participants from 534 sites from January 6, 2017, through December 4, 2020, with follow-up to March 4, 2023. Interventions Participants were randomized (stratified for hormone receptor status [positive vs negative], body mass index [≤30 vs &amp;gt;30], stage II vs III, and time since diagnosis [&amp;lt;18 vs ≥18 months]) to receive 300 mg of aspirin (n = 1510) or placebo once daily (n = 1510) for 5 years. Main Outcomes and Measures The primary outcome was invasive disease–free survival. Overall survival was a key secondary outcome. Results A total of 3020 participants were randomized when the data and safety monitoring committee recommended suspending the study at the first interim analysis because the hazard ratio had crossed the prespecified futility bound. By median follow-up of 33.8 months (range, 0.1-72.6 months), 253 invasive disease–free survival events were observed (141 in the aspirin group and 112 in the placebo group), yielding a hazard ratio of 1.27 (95% CI, 0.99-1.63; P = .06). All invasive disease–free survival events, including death, invasive progression (both distant and locoregional), and new primary events, were numerically higher in the aspirin group, although the differences were not statistically significant. There was no difference in overall survival (hazard ratio, 1.19; 95% CI, 0.82-1.72). Rates of grades 3 and 4 adverse events were similar in both groups. Conclusion and Relevance Among participants with high-risk nonmetastatic breast cancer, daily aspirin therapy did not improve risk of breast cancer recurrence or survival in early follow-up. Despite its promise and wide availability, aspirin should not be recommended as an adjuvant breast cancer treatment. Trial Registration ClinicalTrials.gov Identifier: NCT02927249
Arsenic Exposure in Well Water From the Perspective of Patients and Providers
Jegen, Dominika , Maxson, Julie, Bernard, Matthew , Foss, Randy , Hidaka, Brandon H. , Passmore, Rachael , Sosso, Jessica , Stacey, Stephen K , Thacher, Tom D. , Fischer, Karen, Foss, Randy , Hidaka, Brandon , Passmore, Rachael , Thacher, Thomas D , Jegen, Dominika A , Fischer, Karen

Mayo Clinic

Journal of Primary Care & Community Health | April 29, 2024 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/21501319241247984 | PMID 38682480 Get It

Background: Arsenic is a well-known toxin which may contaminate household water. It is harmful when ingested over prolonged periods of time. As a result, public health experts recommend that water should be screened and treated to prevent arsenic ingestion. In the United States, the responsibility of testing and treatment of private wells falls on homeowners. Despite recommendations for routine screening, this is rarely done. Objectives: To assess the prevalence of well water use in a Midwestern patient population, how patients and clinicians perceive the risks of arsenic in well water, and whether additional resources on well water testing are desired. These findings will be used to influence tools for clinicians regarding symptom and examination findings of chronic arsenic exposure and potentiate the distribution of informational resources on well water testing. Methods: Surveys were sent via email to all actively practicing primary care clinicians at the Mayo Clinic in the United States Midwest, and all active adult patients at the Mayo Clinic in the same region. Our team analyzed survey data to determine whether both patients and clinicians are aware of the health effects of chronic arsenic toxicity from well water, the need for routine well water testing and whether each group wants more information on the associated risks. Results: Both patients and primary care clinicians worry about arsenic exposure. Patients with well water are concerned about their water safety yet feel uninformed about testing options. Clinicians do not know how prevalent well water use is among their patients, feel uninformed about the chronic risks of arsenic exposure and the physical examination associated with it. Both groups unanimously want more information on testing options. Conclusions: Our findings show a significant reliance on well water use in the American Midwest, and unanimous support for the need for further well water testing information and resources for patients and their clinicians.
Defining primary refractory large B-cell lymphoma
Bock, Allison M. , Mwangi, Raphael , Wang, Yucai , Khurana, Arushi , Maurer, Matthew J. , Ayers, Amy , Cohen, Jonathon B. , Casulo, Carla , Lossos, Izidore S. , Reicks, Tanner W., Flowers, Christopher R. , Nowakowski, Grzegorz S. , Cohen, Jonathon B , Casulo, Carla , Lossos, Izidore S , Farooq, Umar , Reicks, Tanner, Witzig, T.E. , Cerhan, James R , Nastoupil, Loretta J , Maurer, Matthew , Wang, Yucai , Kahl, Brad S. , Martin, Peter, Ayyappan, Sabarish Ram , Habermann, Thomas M. , Witzig, Thomas E. , Cerhan, James R. , Nastoupil, Loretta J.

Mayo Clinic

Blood Advances | April 26, 2024 | Volume: 8 | Issue: 13 | Pages: 3402-3415

10.1182/bloodadvances.2024012760 | PMID 38669353 Get It

Abstract Patients with large B-cell lymphoma (LBCL) that fail to achieve a complete response (CR) or who relapse early after anthracycline-containing immunochemotherapy (IC) have a poor prognosis and are commonly considered to have “primary refractory disease.” However, different definitions of primary refractory disease are used in the literature and clinical practice. In this study, we examined variation in the time to relapse used to define refractory status and association with survival outcomes in patients with primary refractory LBCL in a single-center prospective cohort with validation in an independent multicenter cohort. Patients with newly diagnosed LBCL were enrolled in the Molecular Epidemiological Resource cohort (MER; N = 949) or the Lymphoma Epidemiology of Outcomes cohort (LEO; N = 2755) from September 2002 to May 2021. Primary refractory LBCL was defined as no response (stable disease [SD]) or progressive disease (PD) during, or by the end of, frontline (1L) IC (primary PD; PPD); partial response at end of treatment (EOT PR); or relapse within 3 to 12 months after achieving CR at EOT to 1L IC (early relapse). In the MER cohort, patients with PPD had inferior overall survival (OS; 2-year OS rate: 15% MER, 31% LEO) when compared with other subgroups considered in defining primary refractory disease, EOT PR (2-year OS rate: 38% MER, 50% LEO) and early relapse (2-year OS rate: 44% MER, 58% LEO). Among patients receiving 1L IC with curative intent, we identified that patients with PPD are the key subgroup with poor outcomes. We propose a definition of primary refractory LBCL as SD or PD during, or by the end of, 1L treatment.
The Modified Reactive Strength Index Is a Valid Measure of Lower-Body Explosiveness in Male and Female High School Athletes
Witte, Brandon C., Schouten, Tyler C., Westphal, Jessica A., VanZile, Adam W., Jones, Daniel D., Widenhoefer, Tricia L., Dobbs, Ward C. , Luedke, Joel, Luedke, Joel A, Jones, Daniel D., Jagim, Andrew R. , Almonroeder, Thomas Gus

Mayo Clinic

Journal of Strength & Conditioning Research | April 25, 2024 | Volume: 38 | Issue: 8 | Pages: 1428-1432

10.1519/jsc.0000000000004806 | PMID 38662946 Get It

Abstract Witte, BC, Schouten, TC, Westphal, JA, VanZile, AW, Jones, DD, Widenhoefer, TL, Dobbs, WC, Jagim, AR, Luedke, JA, and Almonroeder, TG. The modified reactive strength index is a valid measure of lower-body explosiveness in male and female high school athletes. J Strength Cond Res 38(8): 1428–1432, 2024—The modified reactive strength index (mRSI) is a commonly used metric to quantify lower-body explosiveness during countermovement jump (CMJ) performance. However, few studies have attempted to examine its validity as a measure of explosiveness, particularly among high school athletes. The purpose of this study was to examine the validity of the mRSI as a measure of lower-body explosiveness among a relatively large sample of male and female high school athletes from various sports. As part of this study, male ( n = 132) and female ( n = 43) high school athletes performed CMJs, while ground reaction forces were recorded using a force platform. The vertical ground reaction force data collected during the CMJs were used to derive the following variables: peak force (PF), peak power, time to PF, time to take-off, peak rate of force development, and the mRSI. Principal component analysis was applied and reduced these variables into 2 components related to “force” and “speed.” The mRSI loaded on both the force (loading = 0.82) and speed (loading = −0.46) components, indicating that it incorporates elements of both force and speed, although it loaded more strongly on the force component than the speed component. The observed pattern of cross-loading suggests that the mRSI is generally a valid measure of lower-body explosiveness for male and female high school athletes.
Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Dodd, Daniel O , Mechaussier, Sabrina , Yeyati, Patricia L. , McPhie, Fraser , Anderson, Jacob R. , Khoo, Chen Jing , Shoemark, Amelia , Gupta, Deepesh Kumar , Attard, Thomas, Zariwala, Maimoona A. , Legendre, Marie , Bracht, Diana , Gui, Miao , Parry, David , Black, Holly A. , Mitri-Frangieh, Rana, Faucon, Catherine, Kaplan, Josseline, Megaw, Roly , Mohamed, Mai A., Aitken, Stuart , Gautier, Philippe , Reinholt, Finn R., Hirst, Robert A. , O’Callaghan, Chris, Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Kenia, Priti , Amiel, Jeanne , Bacci, Giacomo Maria , Calogero, Claudia , Palazzo, Viviana , Tiberi, Lucia , Blümlein, Ulrike, Rogers, Andrew, Wenger, David A. , Fulton, Anne B. , Rosenfeld, Margaret , Holm, Ingrid A., Quigley, Alan J. , Murphy, Laura C. , Cassidy, Diane M. , Kriegsheim, Alex von , Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Murris, Marlène , Hogg, Claire , Macleod, Kenneth , Urquhart, Don S. , Unger, Stefan , Amselem, Serge , Leigh, Margaret W. , Knowles, Michael R. , Mitchison, Hannah M. , Rozet, Jean‐Michel , Mill, Pleasantine , Gupta, Deepesh K , Wallmeier, Julia , Fassad, Mahmoud R , Tennant, Peter A , Meynert, Alison , Wheway, Gabrielle , Fares-Taie, Lucas , Black, Holly A , Patel, Mitali , McKie, Lisa , Megaw, Roly , Aitken, Stuart , Gautier, Philippe , Heimdal, Ketil , Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Jabs, Ethylin W , Bacci, Giacomo Maria , Calogero, Claudia , Tiberi, Lucia , Wambach, Jennifer A , Wegner, Daniel J , Fulton, Anne B , Kenna, Margaret , Quigley, Alan , Hall, Emma A , Murphy, Laura C , Cassidy, Diane M , von Kriegsheim, Alex , Pasquier, Laurent , Murris, Marlène S , Chalmers, James D , Hogg, Claire , Macleod, Kenneth A , Urquhart, Don S , Unger, Stefan , Aitman, Timothy J , Leigh, Margaret W , Omran, Heymut , Mitchison, Hannah M , Brown, Alan , Marsh, Joseph A , Ti, Shih-Chieh , Horani, Amjad , Rozet, Jean-Michel , Perrault, Isabelle , Mill, Pleasantine , Dodd, Daniel O. , Mechaussier, Sabrina , Gatsogiannis, Christos , Holm, Ingrid A., Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Papon, Jean‐François , Pasquier, Laurent , Chalmers, James D. , Omran, Heymut , Welburn, Julie P. I.

Mayo Clinic

Science | April 25, 2024 | Volume: 384 | Issue: 6694 | Pages: No page available

10.1126/science.adf5489 | PMID 38662826 Get It

Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.